Updated:
Monograph Capital Advisors
Monograph Capital Advisors is an asset manager based in London; the Altss profile covers its classification, headquarters, registration, AUM band, and key...
Overview
Monograph Capital Advisors (UK), LLP is a London-based investment adviser since 2021.
General information
Firm type
Asset Manager
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Principals
Tim Clayton
Managing Partner
Freddie Dear
Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Monograph Capital?
Investment decisions are led by Managing Partners Tim Clayton and Freddie Dear. Clayton brings a physician-scientist perspective from his tenure at AstraZeneca's MedImmune division, while Dear contributes strategy and operational expertise from the same organization. The firm maintains a flat partnership structure with a small investment committee that evaluates each opportunity against the firm's platform-biotech thesis.
What geographies does Monograph Capital invest in?
Monograph's core geographic focus is the United Kingdom and continental Europe, where the firm believes transformative academic science has been historically underserved by long-duration venture capital. The firm selectively invests in the United States when opportunities align with its platform-building strategy and syndicate preferences.
What is Monograph Capital's relationship to AstraZeneca?
Monograph's founding partners Tim Clayton and Freddie Dear are both former executives at AstraZeneca's biologics research and development arm, MedImmune. This lineage informs the firm's clinical-development operating model, but Monograph operates as an independent investment firm with no formal affiliation or exclusive pipeline arrangement with AstraZeneca.
Does Monograph Capital invest in single-asset biotech startups?
No. Monograph's stated strategy explicitly targets platform biotechnology companies — those developing multiple therapeutic candidates against validated biological pathways. The firm avoids single-asset stories where the entire enterprise value rests on one preclinical or early-clinical program, as these do not align with its concentration model and multi-decade holding period.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: